Trial Profile

A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480 [ispronicline]/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Jan 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ispronicline (Primary) ; Aripiprazole
Indications Alzheimer's disease; Bipolar disorders; Depressive disorders; Schizophrenia
Focus Pharmacokinetics

30 Jun 2009 Status changed from suspended to completed, according to ClinicalTrials.gov.
15 Jan 2009 Status changed from recruiting to suspended due to the observation of a serious adverse event in another ispronicline trial according to ClinicalTrials.gov; this trial has been temporarily suspended during further evaluation.
24 Sep 2008 Planned end date changed from 1 Aug 2008 to 1 Apr 2009 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com